Syndax Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with cancer. Their pipeline is built on two core platforms: an inhibitor of the Menin-MLL interaction, revumenib (SNDX-5613), and an anti-CSF-1R antibody, axatilimab (SNDX-6352). These candidates target oncogenic pathways and modulate the tumor microenvironment, respectively, with the goal of addressing unmet medical needs in various hematologic malignancies and solid tumors. Syndax is dedicated to advancing its drug candidates through rigorous clinical trials to bring meaningful new treatments to cancer patients.
The Waltham headquarters serves as the central nexus for Syndax's corporate strategy, research and development oversight, clinical operations management, financial activities, and business development efforts.
Located within a modern office park that caters to life science companies, offering facilities conducive to collaboration and scientific advancement.
The work culture at Syndax is characterized by a strong scientific focus, collaborative teamwork, and a patient-centric mission. Employees are driven by the pursuit of innovative cancer therapies and a commitment to making a difference in patients' lives.
Its location in the Boston-Cambridge biotech cluster provides strategic advantages, including access to a rich talent pool, world-class research institutions, and a vibrant network of potential collaborators and service providers.
While Syndax Pharmaceuticals is headquartered in the United States, its operational reach is global, primarily through the execution of clinical trials. The company collaborates with clinical research organizations (CROs), investigators, and trial sites in North America, Europe, and other regions as necessary to advance its pipeline of cancer therapies. This global approach is essential for recruiting diverse patient populations and navigating multinational regulatory pathways for drug development.
35 Gatehouse Drive, Building D, Floor 3
Waltham
MA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Syndax Pharmaceuticals' leadership includes:
Syndax Pharmaceuticals has been backed by several prominent investors over the years, including:
Syndax Pharmaceuticals has focused on strengthening its leadership team, particularly in commercial and financial roles, reflecting its progress towards potential commercialization. Key appointments have been made to bolster these functions.
Discover the tools Syndax Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Syndax Pharmaceuticals likely utilizes common corporate email patterns, typically combining an employee's first initial and last name, or first name and last name separated by a dot.
[first_initial][last]@syndax.com
Format
mmetzger@syndax.com
Example
80%
Success rate
Syndax Pharmaceuticals Press Release • May 29, 2024
Syndax announced it will present updated data from its revumenib clinical trials, including the BEAT-AML and AUGMENT-101 studies, at the upcoming EHA2024 Congress. These presentations will highlight efficacy and safety in patients with relapsed/refractory acute leukemias....more
Syndax Pharmaceuticals Press Release • May 7, 2024
Syndax reported its Q1 2024 financial results, detailing its cash position and operational progress. Key updates included advancements in the revumenib and axatilimab programs, with expectations for NDA submission for revumenib and pivotal trial initiation for axatilimab in cGVHD....more
Syndax Pharmaceuticals Press Release • April 2, 2024
Syndax announced presentations of new preclinical and clinical data for both axatilimab and revumenib at the American Association for Cancer Research (AACR) Annual Meeting 2024, further showcasing the potential of its pipeline....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Syndax Pharmaceuticals, are just a search away.